UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/214,701	09/30/1999	GEORGE H. LOWELL	484112.408USPC	8314
SEED INTELLECTUAL PROPERTY LAW GROUP PLLC 701 FIFTH AVE			EXAMINER	
			PARKIN, JEFFREY S	
SUITE 5400 SEATTLE, WA 98104		ART UNIT	PAPER NUMBER	
			1648	
			MAIL DATE	DELIVERY MODE
			11/19/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

·						
	Application No.	Applicant(s)				
	09/214,701	LOWELL ET AL.				
Office Action Summary	Examiner	Art Unit				
	Jeffrey S. Parkin, Ph.D.	1648				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period was realiure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tin will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1)⊠ Responsive to communication(s) filed on <u>23 August 2007</u> .						
2a)⊠ This action is <b>FINAL</b> . 2b)☐ This	This action is <b>FINAL</b> . 2b) This action is non-final.					
	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4) Claim(s) 33,34,38 and 39 is/are pending in the 4a) Of the above claim(s) is/are withdray 5) Claim(s) is/are allowed. 6) Claim(s) 33, 34, 38, and 39 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or	wn from consideration.					
Application Papers						
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) accomposed and applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Examine	epted or b) objected to by the drawing(s) be held in abeyance. Se tion is required if the drawing(s) is ob	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).				
Priority under 35 U.S.C. § 119	·					
12) Acknowledgment is made of a claim for foreign  a) All b) Some * c) None of:  1. Certified copies of the priority document  2. Certified copies of the priority document  3. Copies of the certified copies of the priority document  application from the International Bureau  * See the attached detailed Office action for a list	s have been received. s have been received in Applicat rity documents have been receive u (PCT Rule 17.2(a)).	ion No ed in this National Stage				
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08)  Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail D 5) Notice of Informal F 6) Other:	ate				

Serial No.: 09/214,701 Docket No.: 406462000200 Applicants: Lowell, G., et al. Filing Date: 09/30/99

### Detailed Office Action

### Status of the Claims

Acknowledgement is hereby made of receipt and entry of the communication filed 23 August, 2007. Claims 33, 34, 38, and 39 are pending in the instant application.

## 35 U.S.C. § 103(a)

The following is a quotation of 35 U.S.C. § 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Subject matter developed by another person, which qualifies as prior art only under subsection (f) or (g) of section 102 of this title, shall not preclude patentability under this section where the subject matter and the claimed invention were, at the time the invention was made, owned by the same person or subject to an obligation of assignment to the same person.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. § 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 C.F.R. § 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. § 103(c) and potential 35

Serial No.: 09/214,701 Applicants: Lowell, G., et al.

U.S.C. § 102(f) or (g) prior art under 35 U.S.C. § 103(a).

<u>ہ</u> .

Claims 33, 34, 38, and 39 stand rejected under 35 U.S.C. § 103(a) as being unpatentable over Sarngadharan et al. (1992) in view of Lowell (1998) and Anselem et al. (1998). The amended claims are directed toward a method for the induction of anti-HIV neutralizing antibodies by administering a composition comprising a gp160, proteosome, and bioadhesive C-terminal truncated nanoemulsion. As previously set forth, Sarngadharan and colleagues provide an oligomeric truncated gp160 obtained from a chronically infected HIV-I451 cell line. This is the same antigen employed by applicants. Lowell provides art-recognized methods for increasing the immunogenicity of an immungenic preparation through the administration of proteosomes and hydrophobic anchors. Anselem and associates teach that the addition of bioadhesive nanoemulsions increases the immunogenicity of an immunogen. Therefore, it would have been prima facie obvious to one of ordinary skill in the art at the time of the invention to prepare an immunogenic composition comprising the recombinant oligomeric et al. (1992), the proteosomes gp160 of Sarngadharan hydrophobic anchor of Lowell (1998),and the bioadhesive nanoemulsion of Anselem et al. (1998). One of ordinary skill in the art would have been motivated to employ both proteosomes and nanoemulsions since the prior art demonstrates that these reagents increase the immunogenicity of any given immunogen. Therefore, their inclusion in an immunogenic composition would be expected to increase the immunogenicity of the immunogen of interest. One of ordinary skill in the art would have also been motivated to administer this composition to mucosal sites since HIV is a sexually transmitted disease. Strong mucosal immune responses should prove useful in combating HIV infection. Applicants'

Serial No.: 09/214,701 Applicants: Lowell, G., et al.

arguments have been carefully considered but are not deemed to be persuasive for the reasons of record set forth *supra*.

# Finality of Office Action

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 C.F.R. § 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 C.F.R. § 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

### Correspondence

Any inquiry concerning this communication should be directed to Jeffrey S. Parkin, Ph.D., whose telephone number is (571) 272-0908. The examiner can normally be reached Monday through Thursday from 10:30 AM to 9:00 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner are unsuccessful, the examiner's supervisor, Bruce R. Campell, Ph.D., can be reached at (571) 272-0974. Direct general status inquiries to the Technology Center 1600 receptionist at (571) 272-1600. Informal communications may be submitted to the Examiner's RightFAX account at (571) 273-0908.

Applicants are reminded that the United States Patent and Trademark Office (Office) requires most patent related correspondence to be: a) faxed to the Central FAX number (571-273-8300) (updated as of July 15, 2005), b) hand carried or delivered to the Customer Service Window (now located at the Randolph Building, 401 Dulany Street, Alexandria, VA 22314), c) mailed to the mailing address set forth in 37 C.F.R. § 1.1 (e.g., P.O. Box

Serial No.: 09/214,701 Applicants: Lowell, G., et al.

1450, Alexandria, VA 22313-1450), or d) transmitted to the Office using the Office's Electronic Filing System. This notice replaces all prior Office notices specifying a specific fax number or hand carry address for certain patent related correspondence. For further information refer to the <u>Updated Notice of Centralized Delivery and Facsimile Transmission Policy for Patent Related Correspondence</u>, and Exceptions Thereto, 1292 Off. Gaz. Pat. Office 186 (March 29, 2005).

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Respectfully,

feffrey S. Parkin, Ph.D.

Primary Examiner Art Unit 1648

12 November, 2007